Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MDXG's Cash to Debt is ranked higher than
90% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. MDXG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MDXG' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.68
MDXG's Equity to Asset is ranked higher than
59% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MDXG: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
MDXG' s Equity to Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.8 Max: 0.89
Current: 0.68
0.44
0.89
Interest Coverage 54.29
MDXG's Interest Coverage is ranked lower than
52% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 73.78 vs. MDXG: 54.29 )
Ranked among companies with meaningful Interest Coverage only.
MDXG' s Interest Coverage Range Over the Past 10 Years
Min: 54.29  Med: 5141.65 Max: No Debt
Current: 54.29
F-Score: 5
Z-Score: 11.97
M-Score: -1.32
WACC vs ROIC
10.70%
23.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 7.70
MDXG's Operating margin (%) is ranked higher than
64% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. MDXG: 7.70 )
Ranked among companies with meaningful Operating margin (%) only.
MDXG' s Operating margin (%) Range Over the Past 10 Years
Min: -1334.98  Med: -12.13 Max: 13.01
Current: 7.7
-1334.98
13.01
Net-margin (%) 8.75
MDXG's Net-margin (%) is ranked higher than
73% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. MDXG: 8.75 )
Ranked among companies with meaningful Net-margin (%) only.
MDXG' s Net-margin (%) Range Over the Past 10 Years
Min: -1447.4  Med: -17.64 Max: 15.72
Current: 8.75
-1447.4
15.72
ROE (%) 17.50
MDXG's ROE (%) is ranked higher than
85% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. MDXG: 17.50 )
Ranked among companies with meaningful ROE (%) only.
MDXG' s ROE (%) Range Over the Past 10 Years
Min: -566.67  Med: -113.28 Max: 29.85
Current: 17.5
-566.67
29.85
ROA (%) 12.45
MDXG's ROA (%) is ranked higher than
89% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. MDXG: 12.45 )
Ranked among companies with meaningful ROA (%) only.
MDXG' s ROA (%) Range Over the Past 10 Years
Min: -557.14  Med: -81.88 Max: 24.02
Current: 12.45
-557.14
24.02
ROC (Joel Greenblatt) (%) 33.58
MDXG's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. MDXG: 33.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDXG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2458.54  Med: -537.87 Max: 71.75
Current: 33.58
-2458.54
71.75
Revenue Growth (3Y)(%) 70.80
MDXG's Revenue Growth (3Y)(%) is ranked higher than
98% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. MDXG: 70.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDXG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 261.7
Current: 70.8
0
261.7
» MDXG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MDXG Guru Trades in Q4 2015

Jim Simons 19,600 sh (New)
Paul Tudor Jones 36,500 sh (+22.90%)
Steven Cohen 908,600 sh (+10.41%)
Joel Greenblatt Sold Out
» More
Q1 2016

MDXG Guru Trades in Q1 2016

Jim Simons 85,500 sh (+336.22%)
Steven Cohen Sold Out
Paul Tudor Jones 34,800 sh (-4.66%)
» More
Q2 2016

MDXG Guru Trades in Q2 2016

Steven Cohen 150,000 sh (New)
Joel Greenblatt 15,559 sh (New)
Jim Simons Sold Out
Paul Tudor Jones 17,800 sh (-48.85%)
» More
Q3 2016

MDXG Guru Trades in Q3 2016

Joel Greenblatt 61,422 sh (+294.77%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NAS:CYNO, NAS:SPNC, NAS:VASC, NAS:CNMD, OTCPK:IOBCF, NYSE:ITGR, NAS:CSII, NAS:INGN, NAS:KTWO, NAS:BABY, NAS:OFIX, NYSE:CRY, NAS:GNMK, NAS:ZLTQ, OTCPK:MZRTF, NAS:ARAY, NAS:EXAC, NYSE:IVC, OTCPK:NMRD, OTCPK:IPDQF » details
Traded in other countries:MXE.Germany,
MiMedx Group Inc is a developer, manufacturer and marketer of patent-protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.

MiMedx Group Inc was incorporated in Florida on February 28, 2008. The Company develops clinical solutions for the use of its biomaterials to regenerate soft tissue in wound healing, orthopedics and other specialty fields of medicine. It is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFixM, and its tissue technologies, AmnioFix and EpiFix. It is a supplier of allografts processed from amniotic tissue, having supplied approximately over 200,000 allografts to date for application in the Surgical, Orthopedic, Spinal, Wound Care, Ophthalmic, and Dental segments of healthcare. Its technology and products are Purion, AmnioFix, EpiFix and other Tissue -Based Allografts and Medical Devices- CollaFix and HydroFix. The Company operates a licensed tissue bank. Its solutions are being used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds.

Ratios

vs
industry
vs
history
P/E(ttm) 53.33
MDXG's P/E(ttm) is ranked lower than
73% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.16 vs. MDXG: 53.33 )
Ranked among companies with meaningful P/E(ttm) only.
MDXG' s P/E(ttm) Range Over the Past 10 Years
Min: 28.08  Med: 53.11 Max: 1843.33
Current: 53.33
28.08
1843.33
Forward P/E 33.00
MDXG's Forward P/E is ranked lower than
80% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 21.74 vs. MDXG: 33.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 53.33
MDXG's PE(NRI) is ranked lower than
72% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.53 vs. MDXG: 53.33 )
Ranked among companies with meaningful PE(NRI) only.
MDXG' s PE(NRI) Range Over the Past 10 Years
Min: 28.08  Med: 53.11 Max: 1843.33
Current: 53.33
28.08
1843.33
P/B 8.49
MDXG's P/B is ranked lower than
83% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. MDXG: 8.49 )
Ranked among companies with meaningful P/B only.
MDXG' s P/B Range Over the Past 10 Years
Min: 5.63  Med: 9.96 Max: 22
Current: 8.49
5.63
22
P/S 4.73
MDXG's P/S is ranked lower than
65% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. MDXG: 4.73 )
Ranked among companies with meaningful P/S only.
MDXG' s P/S Range Over the Past 10 Years
Min: 3.64  Med: 10.93 Max: 825
Current: 4.73
3.64
825
PFCF 184.43
MDXG's PFCF is ranked lower than
94% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.13 vs. MDXG: 184.43 )
Ranked among companies with meaningful PFCF only.
MDXG' s PFCF Range Over the Past 10 Years
Min: 48.21  Med: 83.11 Max: 191.73
Current: 184.43
48.21
191.73
POCF 80.57
MDXG's POCF is ranked lower than
93% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 18.20 vs. MDXG: 80.57 )
Ranked among companies with meaningful POCF only.
MDXG' s POCF Range Over the Past 10 Years
Min: 36.4  Med: 59.96 Max: 1830
Current: 80.57
36.4
1830
EV-to-EBIT 59.02
MDXG's EV-to-EBIT is ranked lower than
82% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.46 vs. MDXG: 59.02 )
Ranked among companies with meaningful EV-to-EBIT only.
MDXG' s EV-to-EBIT Range Over the Past 10 Years
Min: -618.7  Med: -7.6 Max: 1158.8
Current: 59.02
-618.7
1158.8
EV-to-EBITDA 44.96
MDXG's EV-to-EBITDA is ranked lower than
82% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 16.23 vs. MDXG: 44.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDXG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -809.7  Med: -8 Max: 994.2
Current: 44.96
-809.7
994.2
Current Ratio 2.56
MDXG's Current Ratio is ranked higher than
52% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. MDXG: 2.56 )
Ranked among companies with meaningful Current Ratio only.
MDXG' s Current Ratio Range Over the Past 10 Years
Min: 0.05  Med: 2.56 Max: 7.08
Current: 2.56
0.05
7.08
Quick Ratio 2.12
MDXG's Quick Ratio is ranked higher than
54% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. MDXG: 2.12 )
Ranked among companies with meaningful Quick Ratio only.
MDXG' s Quick Ratio Range Over the Past 10 Years
Min: 0.05  Med: 2.12 Max: 6.7
Current: 2.12
0.05
6.7
Days Inventory 171.66
MDXG's Days Inventory is ranked lower than
66% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. MDXG: 171.66 )
Ranked among companies with meaningful Days Inventory only.
MDXG' s Days Inventory Range Over the Past 10 Years
Min: 11.88  Med: 121.83 Max: 171.66
Current: 171.66
11.88
171.66
Days Sales Outstanding 102.00
MDXG's Days Sales Outstanding is ranked lower than
74% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. MDXG: 102.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDXG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 74.94  Med: 94.12 Max: 104.76
Current: 102
74.94
104.76
Days Payable 143.85
MDXG's Days Payable is ranked higher than
84% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. MDXG: 143.85 )
Ranked among companies with meaningful Days Payable only.
MDXG' s Days Payable Range Over the Past 10 Years
Min: 88.08  Med: 105.51 Max: 164.89
Current: 143.85
88.08
164.89

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.70
MDXG's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. MDXG: -6.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDXG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -105.6  Med: -32.4 Max: -6.7
Current: -6.7
-105.6
-6.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 21.73
MDXG's Price/Net Current Asset Value is ranked lower than
85% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 6.51 vs. MDXG: 21.73 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDXG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 11.35  Med: 19.5 Max: 147.5
Current: 21.73
11.35
147.5
Price/Tangible Book 15.17
MDXG's Price/Tangible Book is ranked lower than
86% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 4.06 vs. MDXG: 15.17 )
Ranked among companies with meaningful Price/Tangible Book only.
MDXG' s Price/Tangible Book Range Over the Past 10 Years
Min: 10.61  Med: 19.88 Max: 316.67
Current: 15.17
10.61
316.67
Price/Projected FCF 8.24
MDXG's Price/Projected FCF is ranked lower than
84% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 1.97 vs. MDXG: 8.24 )
Ranked among companies with meaningful Price/Projected FCF only.
MDXG' s Price/Projected FCF Range Over the Past 10 Years
Min: 7.4  Med: 18.03 Max: 354.5
Current: 8.24
7.4
354.5
Price/Median PS Value 0.43
MDXG's Price/Median PS Value is ranked higher than
89% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. MDXG: 0.43 )
Ranked among companies with meaningful Price/Median PS Value only.
MDXG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 0.98 Max: 70
Current: 0.43
0.39
70
Price/Graham Number 5.98
MDXG's Price/Graham Number is ranked lower than
82% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 2.31 vs. MDXG: 5.98 )
Ranked among companies with meaningful Price/Graham Number only.
MDXG' s Price/Graham Number Range Over the Past 10 Years
Min: 4.07  Med: 5.57 Max: 24.59
Current: 5.98
4.07
24.59
Earnings Yield (Greenblatt) (%) 1.68
MDXG's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. MDXG: 1.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDXG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.8 Max: 2.9
Current: 1.68
0.1
2.9

More Statistics

Revenue (TTM) (Mil) $227.0
EPS (TTM) $ 0.18
Beta1.11
Short Percentage of Float22.75%
52-Week Range $6.64 - 10.02
Shares Outstanding (Mil)109.51

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 245 301 361
EPS ($) 0.22 0.29 0.35
EPS w/o NRI ($) 0.22 0.29 0.35
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MDXG

Headlines

Articles On GuruFocus.com
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
ETFs with exposure to MiMedx Group, Inc. : December 9, 2016 Dec 09 2016
MiMedx to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 18 2016
MIMEDX GROUP, INC. Financials Nov 16 2016
MiMedx To Present At The Canaccord|Genuity Medical Technology And Diagnostics Forum Nov 11 2016
MIMEDX GROUP, INC. Files SEC form 10-Q, Quarterly Report Nov 08 2016
Coverage initiated on MiMedx Group by Aegis Capital Nov 08 2016
MiMedx Group, Inc. breached its 50 day moving average in a Bearish Manner : MDXG-US : November 4,... Nov 04 2016
MiMedx Announces USP-NF Monograph For dHACM Allografts Has Published Nov 03 2016
ETF’s with exposure to MiMedx Group, Inc. : November 1, 2016 Nov 01 2016
MiMedx Group, Inc. :MDXG-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016 Oct 31 2016
Edited Transcript of MDXG earnings conference call or presentation 27-Oct-16 2:30pm GMT Oct 28 2016
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 27 2016
MiMedx Announces Third Quarter 2016 Results Oct 27 2016
Q3 2016 MiMedx Group Inc Earnings Release - Before Market Open Oct 27 2016
MiMedx Is Grand Sponsor Of Desert Foot 2016 Oct 18 2016
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 12 2016
MiMedx Third Quarter 2016 Revenue Exceeds Upper End of Guidance Oct 10 2016
Advances In Regenerative Medicine With MiMedx EpiFix® And AmnioFix® To Be Presented At SAWC Fall... Oct 06 2016
MiMedx at the 5th Congress of World Union Wound Healing Societies Sep 29 2016
MiMedx Urges FDA To Reconsider Draft Guidances During Hearing Sep 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)